文献速递脑血管病

西洛他唑与阿司匹林在高脑出血风险缺血性卒中患者中的比较:PICASSO 试验亚组分析

Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
PubMed 文献 · Stroke · 2019-12-20

PICASSO 试验亚组分析纳入 1534 例有脑出血史或多发微出血的缺血性卒中患者,随机接受西洛他唑或阿司匹林治疗,平均随访 1.8 年。结果显示,西洛他唑组出血性卒中在多发微出血患者中显著少于阿司匹林组(1 vs 13 例;HR 0.08,95%CI 0.01-0.61;P=0.01)。在轻至中度白质病变患者中,西洛他唑显著降低任何卒中风险。

要点

  • 多发微出血患者使用西洛他唑出血性卒中风险显著低于阿司匹林。
  • 轻至中度白质病变患者使用西洛他唑任何卒中风险显著降低。
  • 西洛他唑组随访时心率和 HDL 胆固醇水平显著高于阿司匹林组。

核心结论

  • 西洛他唑可能对伴多发脑微出血且白质病变尚不广泛的缺血性卒中患者更有利。

研究设计与样本

  • PICASSO 试验的亚组分析,纳入既往脑出血或多发微出血的缺血性卒中患者,随机接受西洛他唑或阿司匹林治疗,平均随访 1.8 年。

主要发现

  • 在全部 1534 例入组患者中,治疗组与高脑出血风险指数对出血性卒中交互作用显著(P for interaction=0.03)。
  • 多发微出血患者中,西洛他唑组出血性卒中 1 例,阿司匹林组 13 例(HR 0.08,95%CI 0.01-0.61;P=0.01)。
  • 治疗组与白质改变对任何卒中的交互作用边缘显著(P for interaction=0.08)。
  • 轻度白质改变患者中,西洛他唑组任何卒中 5 例,阿司匹林组 16 例(HR 0.36,95%CI 0.13-0.97;P=0.04)。
  • 中度白质改变患者中,西洛他唑组任何卒中 16 例,阿司匹林组 32 例(HR 0.50,95%CI 0.29-0.92;P=0.03)。

临床怎么用

  • 对于伴多发脑微出血且白质病变尚不广泛的缺血性卒中患者,可考虑选用西洛他唑而非阿司匹林以降低出血性卒中及任何卒中风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Although cilostazol has shown less hemorrhagic events than aspirin, only marginal difference was observed in hemorrhagic stroke events among patients at high risk for cerebral hemorrhage. To identify patients who would most benefit from cilostazol, this study analyzed interactions between treatment and subgroups of the PICASSO trial (Prevention of Cardiovascular Events in Asian Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage). Methods- Ischemic stroke patients with a previous intracerebral hemorrhage or multiple microbleeds were randomized to treatment with cilostazol or aspirin and followed up for a mean 1.8 years. Efficacy, defined as the composite of any stroke, myocardial infarction, and vascular death, and safety, defined as the incidence of hemorrhagic stroke, were analyzed in the 2 groups. Interactions between treatment and age, sex, presence of hypertension and diabetes mellitus, index of high-risk cerebral hemorrhage, and white matter lesion burden were analyzed for primary and key secondary outcomes. Changes in vital signs and laboratory results were compared in the 2 groups. Results- Among all 1534 patients enrolled, a significant interaction between treatment group and index of high risk for cerebral hemorrhage on hemorrhagic stroke (P for interaction, 0.03) was observed. Hemorrhagic stroke was less frequent in the cilostazol than in the aspirin group in patients with multiple microbleeds (1 versus 13 events; hazard ratio, 0.08 [95% CI, 0.01-0.61]; P=0.01). A marginal interaction between treatment group and white matter change on any stroke (P for interaction, 0.08) was observed. Cilostazol reduced any stroke significantly in patients with mild (5 versus 16 events; hazard ratio, 0.36 [95% CI, 0.13-0.97]; P=0.04)-to-moderate (16 versus 32 events; hazard ratio, 0.50 [95% CI, 0.29-0.92]; P=0.03) white matter changes. Heart rate and HDL (high-density lipoprotein) cholesterol level were significantly higher in the cilostazol group than in the aspirin group at follow-up. Conclusions- Cilostazol may be more beneficial for ischemic stroke patients with multiple cerebral microbleeds and before white matter changes are extensive. Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT01013532.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kim BJ, Kwon SU, Park JH, et al. Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial. Stroke. 2019. PMID: 31856691. doi:10.1161/STROKEAHA.119.023855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。